Hancock Whitney Corp Sells 4,266 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Hancock Whitney Corp lowered its stake in Zynex, Inc. (NASDAQ:ZYXI) by 13.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 28,637 shares of the company’s stock after selling 4,266 shares during the period. Hancock Whitney Corp owned approximately 0.09% of Zynex worth $267,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hsbc Holdings PLC bought a new position in Zynex in the 2nd quarter valued at about $113,000. Quest Partners LLC increased its stake in Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after acquiring an additional 11,195 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Zynex during the first quarter valued at approximately $137,000. Principal Financial Group Inc. lifted its stake in Zynex by 10.4% during the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after purchasing an additional 1,846 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Zynex by 32.3% in the 2nd quarter. Sei Investments Co. now owns 21,717 shares of the company’s stock valued at $202,000 after purchasing an additional 5,300 shares in the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Insiders Place Their Bets

In other news, COO Anna Lucsok sold 8,083 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the transaction, the chief operating officer now owns 16,980 shares of the company’s stock, valued at $136,349.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Joshua R. Disbrow bought 7,000 shares of the firm’s stock in a transaction on Monday, July 29th. The stock was acquired at an average price of $8.32 per share, with a total value of $58,240.00. Following the transaction, the director now owns 72,000 shares of the company’s stock, valued at approximately $599,040. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, COO Anna Lucsok sold 8,083 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. The disclosure for this sale can be found here. Insiders own 52.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZYXI shares. Royal Bank of Canada lowered their price target on Zynex from $15.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, July 26th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Zynex in a report on Wednesday, September 4th.

Zynex Stock Down 1.7 %

Shares of NASDAQ:ZYXI opened at $7.98 on Tuesday. Zynex, Inc. has a 52-week low of $7.04 and a 52-week high of $13.77. The company has a market capitalization of $253.56 million, a PE ratio of 34.70 and a beta of 0.54. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.22 and a current ratio of 4.06. The company has a fifty day moving average of $8.33 and a 200-day moving average of $9.91.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, July 25th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $49.88 million during the quarter, compared to the consensus estimate of $51.99 million. Zynex had a net margin of 3.12% and a return on equity of 14.15%. Zynex’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.09 earnings per share. On average, equities analysts predict that Zynex, Inc. will post 0.22 EPS for the current fiscal year.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.